Second-line chemotherapy with gemcitabine and oxaliplatin in combination with loco-regional hyperthermia (EHY-2000) in patients with refractory metastatic pancreatic cancer - preliminary results of a prospective trial

摘要

There is no standard treatment for second-line in patients with metastaticpancreatic cancer. The treatment with local hyperthermia (41"2 C) in order toenhance the activity gemcitabine-oxaliplatin on liver metastasis and primary advancedtumor was added as standard treatment. The primary objective was the response ratewhile the secondary objective were the safety of chemotherapy associated withhyperthermia and overall survival. There were 26 patients included, diagnosed withmetastatic pancreatic cancer with progressive disease after gemcitabine treatment. Thepatients were enrolled in the period January 2005 "May 2011. The patients receivedgemcitabine 1000 mg/msq IV and oxaliplatin 100 mg/msq IV day 1 (GEMOX)combined with locoregional hyperthermia days1, 3 and 5 all repeated at 14 days. From26 patients included, 19 patients had an evaluable response at the treatment. Thetoxicity of chemotherapy for these patients was related with chemotherapy (neutropeniagrade III "24%; anemia grade III "8%, thrombopenia grade III "6%; neurologictoxicity grade III "22%. Toxicity related to hyperthermia was: discomfort because ofbolus pressure (2%), pain related with position (12%), power related pain (2%). Rate ofresponse was stable disease 53%, partial response 18% and progression disease 29%.Progression-free-survival was 3.9 months. Overall survival was 8.9 months.